drugset / Trial / NCT04079179
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2
Recruiting
90 enrolled
Carl Allen
Baylor College of Medicine · collabGenentech, Inc. · collabNorth American Consortium for Histiocytosis · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.
Timeline
- Start
- 2021-04-19
- Primary completion
- 2025-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 40 mg | — |
| Subject | Cobimetinib | Small molecule | 60 mg | — |